Aprogen decides to acquire 10 billion won CB of subsidiary Aprogen Biologics
Subsidiary Aprogen Biologics decides to issue 10 billion won of 19th unregistered unsecured private convertible bonds to parent Aprogen
Conversion price: 4,433 won, coupon rate: 2%, yield to maturity: 4%, maturity: May 29, 2031
Conversion shares: 2,255,808 (15.65% of subsidiary's total outstanding shares)
Proceeds to be used for acquisition of securities of other corporation: 10 billion won investment in Akro New Technology Fund No. 241
Subsidiary's outstanding CB total 128 billion won (including 118 billion won prior issues), convertible into 24,427,092 shares, representing 169.49% of current shares of 14,412,374
Investment amount of 10 billion won is approximately 11.2% of Aprogen's market cap of 89.2 billion won
KOSPI Filing Information
Filing: Major Event Report (Decision on Issuance of Convertible Bonds) (Major Management Matters of Subsidiary)